163 related articles for article (PubMed ID: 38658659)
1. Acute kidney injury during autologous stem cell transplantation in light chain amyloidosis with kidney involvement and their impact on prognosis.
Xu W; Chen W; Guo J; Zhao L; Ren G; Huang X
Bone Marrow Transplant; 2024 Apr; ():. PubMed ID: 38658659
[TBL] [Abstract][Full Text] [Related]
2. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.
Nader R; Zhen A; Angel-Korman A; Pavlovich SS; Pogrebinsky A; Doros G; Menn-Josephy H; Stern L; Sanchorawala V; Havasi A
Nephrol Dial Transplant; 2022 Jun; 37(7):1281-1288. PubMed ID: 34043009
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
Irazabal MV; Eirin A; Gertz MA; Dispenzieri A; Kumar S; Buadi FK; Lacy MQ; Hayman SR; Dingli D; Hogan WJ; Gastineau DA; Glavey SV; Amer H; Leung N
Am J Hematol; 2012 Jan; 87(1):51-4. PubMed ID: 22076913
[TBL] [Abstract][Full Text] [Related]
4. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation.
Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K
Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Engraftment Syndrome following Autologous Stem Cell Transplantation in Light Chain Amyloidosis with Renal Involvement.
Miao F; Ren G; Guo J; Zhao L; Xu W; Huang X
Transplant Cell Ther; 2023 Feb; 29(2):110.e1-110.e8. PubMed ID: 36323398
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Fuchida SI; Kawamura K; Sunami K; Tsukada N; Fujii S; Ohkawara H; Usuki K; Wake A; Endo S; Ishiyama K; Ueda Y; Nakamura Y; Miyamoto T; Fukuda T; Ichinohe T; Atsuta Y; Takamatsu H
Transplant Cell Ther; 2022 Feb; 28(2):76-82. PubMed ID: 34774818
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma.
Andronesi AG; Tanase AD; Sorohan BM; Craciun OG; Stefan L; Varady Z; Lipan L; Obrisca B; Truica A; Ismail G
Cancer Med; 2019 Jun; 8(6):3278-3285. PubMed ID: 31016881
[TBL] [Abstract][Full Text] [Related]
10. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
11. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
[TBL] [Abstract][Full Text] [Related]
12. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
15. Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.
Kim HR; Yoon SE; Kim D; Choi JO; Min JH; Kim BJ; Kim JS; Lee JE; Choi JY; Jeon ES; Kim SJ; Kim K
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):97-103. PubMed ID: 36464620
[TBL] [Abstract][Full Text] [Related]
16. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis.
Dingli D; Tan TS; Kumar SK; Buadi FK; Dispenzieri A; Hayman SR; Lacy MQ; Gastineau DA; Hogan WJ; Gertz MA
Neurology; 2010 Mar; 74(11):913-8. PubMed ID: 20231668
[TBL] [Abstract][Full Text] [Related]
17. The Role of Autologous Stem Cell Transplantation in Amyloidosis.
Vaxman I; Dispenzieri A
Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Vergara-Cadavid J; Johnson PC; Kim HT; Yi A; Sise ME; Leaf DE; Hanna PE; Ho VT; Cutler CS; Antin JH; Gooptu M; Kelkar AH; Wells SL; Nikiforow S; Koreth J; Romee R; Soiffer RJ; Shapiro RM; Gupta S
Transplant Cell Ther; 2023 Jul; 29(7):455.e1-455.e9. PubMed ID: 37015320
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]